Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Company profile
Ticker
DVAX
Exchange
Website
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Dynavax GmbH ...
IRS number
330728374
DVAX stock data
News
Dynavax Technologies Q2 EPS $0.87 Beats $0.22 Estimate, Sales $256.46M Beat $150.99M Estimate
4 Aug 22
Dynavax Technologies: Q2 Earnings Insights
4 Aug 22
Earnings Scheduled For August 4, 2022
4 Aug 22
12 Health Care Stocks Moving In Monday's After-Market Session
25 Jul 22
110 Biggest Movers From Friday
16 May 22
Press releases
Thinking about buying stock in AN2 Therapeutics, AMTD IDEA Group, Dynavax Technologies, Yelp, or Honest Company?
5 Aug 22
Dynavax Reports Second Quarter 2022 Financial Results
4 Aug 22
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 Vaccine
1 Aug 22
Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022
21 Jul 22
European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 Vaccine
20 Jul 22
Investment data
Securities sold
Number of investors
Calendar
4 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Aug 22 | Ryan Spencer | Common Stock | Sell | Dispose S | No | No | 16.9157 | 14,921 | 252.4K | 144,513 |
9 Aug 22 | David F Novack | Common Stock | Sell | Dispose S | No | No | 16.9157 | 26,250 | 444.04K | 53,213 |
9 Aug 22 | Janssen Robert | Common Stock | Sell | Dispose S | No | No | 16.9157 | 7,938 | 134.28K | 35,519 |
8 Aug 22 | Cano Francis | Common Stock | Sell | Dispose S | No | No | 17.17 | 15,000 | 257.55K | 20,834 |
8 Aug 22 | Cano Francis | Common Stock | Option exercise | Acquire M | No | No | 4.97 | 15,000 | 74.55K | 35,834 |
8 Aug 22 | Cano Francis | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.97 | 15,000 | 74.55K | 0 |
8 Aug 22 | Ryan Spencer | Common Stock | Option exercise | Acquire M | No | No | 0 | 29,663 | 0 | 159,434 |
8 Aug 22 | Ryan Spencer | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 29,663 | 0 | 9,887 |
8 Aug 22 | David F Novack | Common Stock | Option exercise | Acquire M | No | No | 0 | 26,250 | 0 | 79,463 |
8 Aug 22 | David F Novack | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 26,250 | 0 | 8,750 |
Institutional ownership, Q1 2022
86.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 203 |
Opened positions | 22 |
Closed positions | 24 |
Increased positions | 73 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 1.1B |
Total shares | 108.87M |
Total puts | 1.23M |
Total calls | 1.27M |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes | 16.54M | $179.27M |
STT State Street | 8.5M | $92.13M |
Bain Capital Life Sciences Investors | 8.42M | $91.22M |
BLK Blackrock | 7.79M | $84.49M |
Bain Capital Life Sciences Fund | 7.63M | $0 |
Chicago Capital | 5.86M | $63.48M |
Vanguard | 5.84M | $63.34M |
Partner Fund Management | 3.81M | $41.25M |
Fisher Asset Management | 3.51M | $38.06M |
Blair William & Co | 2.55M | $27.66M |
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
adware, alleviate, attack, awaiting, belonging, branch, broadly, code, compromise, compromised, conflict, credential, distributor, EC, email, error, extortion, Farma, frequency, hardware, irreparable, Italy, macroeconomic, malware, media, misconduct, Persero, physical, PT, ransomware, ready, Russia, server, software, stuffing, threat, Ukraine, unwilling
Removed:
Bavarian, CHMP, commence, HBV, headwind, Inducement, Israel, lifted, likelihood, Nordic, paused, pose, shift, therapy
Financial reports
Current reports
8-K
Dynavax Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Departure of Directors or Certain Officers
25 May 22
8-K
Dynavax Reports First Quarter 2022 Financial Results
5 May 22
8-K
Entry into a Material Definitive Agreement
16 Mar 22
8-K
Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance
27 Feb 22
8-K
Departure of Directors or Certain Officers
14 Dec 21
8-K
Dynavax Reports Third Quarter 2021 Financial Results
4 Nov 21
8-K
Departure of Directors or Certain Officers
21 Oct 21
8-K
Dynavax Announces Second Quarter 2021 Financial Results
4 Aug 21
8-K
Entry into a Material Definitive Agreement
7 Jul 21
Registration and prospectus
S-8
Registration of securities for employees
2 Jun 22
S-8
Registration of securities for employees
4 Aug 21
S-8
Registration of securities for employees
25 Feb 21
S-3ASR
Automatic shelf registration
6 Aug 20
S-8
Registration of securities for employees
6 Aug 20
S-3ASR
Automatic shelf registration
2 Jul 20
424B5
Prospectus supplement for primary offering
22 May 20
424B5
Prospectus supplement for primary offering
21 May 20
POS AM
Prospectus update (post-effective amendment)
11 Mar 20
POSASR
Automatic shelf registration (post-effective amendment)
11 Feb 20
Proxies
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
17 Apr 20
PRE 14A
Preliminary proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
23 May 19
DEF 14A
Definitive proxy
22 Apr 19
Other
CT ORDER
Confidential treatment order
15 Jul 21
CT ORDER
Confidential treatment order
3 Mar 21
CT ORDER
Confidential treatment order
30 Sep 20
EFFECT
Notice of effectiveness
1 May 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
16 Apr 19
CT ORDER
Confidential treatment order
15 Apr 18
CORRESP
Correspondence with SEC
6 Jul 17
UPLOAD
Letter from SEC
6 Jul 17
UPLOAD
Letter from SEC
5 Jul 17
Ownership
4
DYNAVAX TECHNOLOGIES / Robert Janssen ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / David F Novack ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / Ryan Spencer ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / FRANCIS CANO ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / Justin Burgess ownership change
8 Aug 22
4
DYNAVAX TECHNOLOGIES / Robert Janssen ownership change
8 Aug 22
4
DYNAVAX TECHNOLOGIES / David F Novack ownership change
8 Aug 22
SC 13G
DYNAVAX TECHNOLOGIES / BlackRock ownership change
9 Jun 22
4
DYNAVAX TECHNOLOGIES / Andrew A. F. Hack ownership change
27 May 22
4
DYNAVAX TECHNOLOGIES / Scott Dunseth Myers ownership change
27 May 22
Patents
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
3 Feb 22
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Utility
IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
7 Oct 21
The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
21 Sep 21
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Utility
Combination of a PD-1 Antagonist and CPG-C Type Oligonucleotide for Treating Cancer
1 Jul 21
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
24 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Transcripts
2022 Q2
Earnings call transcript
5 Aug 22
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
28 Feb 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
7 May 21
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
7 May 20
Reddit threads
Breakout Trades - Watchlist 5th August
5 Aug 22
Daily Discussion Thread - August 3rd, 2022
3 Aug 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Is Vroom considered a penny stock yet?
16 Mar 22
Daily Discussion Thread - February 28th, 2022
28 Feb 22
Daily Discussion Thread - February 25th, 2022
25 Feb 22
(12/28) Tuesday's Pre-Market Stock Movers & News
28 Dec 21
(12/28) Tuesday's Pre-Market Stock Movers & News
28 Dec 21
DVAX partner Bio-E completes phase 2 and 3 trials. 🚀🚀🚀 incoming.
9 Nov 21